The FLASH Study: A study of roflumilast versus placebo in patients with asthma (BY217/M2-023)
Study identifier:BY217/M2-023
ClinicalTrials.gov identifier:NCT00076076
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
The FLASH Study: A randomized, controlled study of roflumilast 250 mcg and 500 mcg versus placebo in patients with asthma
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Roflumilast
Sex
All
Actual Enrollment
822
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Dec 2003
Primary Completion Date: -
Study Completion Date: 01 Jun 2005
Study design
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Sept 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
